Skip to main content
Caplight Logo









Datar Cancer Genetics

Datar Cancer Genetics

Private
NashikHealthcare & Life Scienceshttps://datarpgx.com/

Last Round

VC Round

Nov 27, 2024

Company Overview

Datar Cancer Genetics is a molecular oncology company that develops non-invasive diagnostic solutions for cancer, including liquid biopsies for early detection, treatment guidance, and monitoring.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

liquid biopsycancer screeningmolecular oncologyprecision medicinecirculating tumor cellsCTCcell-free DNAcfDNAclinical decision supportmedical AIgenomic profilingearly cancer detectionmulti-omic integrationcancer diagnosticsblood-based testingliquid biopsy testcancer monitoring

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Datar Cancer Genetics Comparables

Compare Datar Cancer Genetics with similar companies based on industry and business-model similarity.

Datar Cancer Genetics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DiaCarta, Inc.
82%
CellMax Life
82%
ClearNote Health
80%

Datar Cancer Genetics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 27, 2024
Series AAug 26, 2024

Datar Cancer Genetics Investors

Notable investors and investment history

Datar Cancer Genetics investors
InvestorRounds
Alkemi Growth CapitalVC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 23, 2025

    Launched NaturaGene-AI, an advanced oncology testing panel.

  • Feb 11, 2025

    Dr. Massimo Cristofanilli appointed as Strategic Advisor.

Datar Cancer Genetics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Datar Cancer Genetics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Datar Cancer Genetics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNashik
Employee Range39
Year Founded1992
Last FundingNov 27, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?